Generally, when a single insider buys stock, it is usually not a big deal. However, when several insiders are buying, like in the case of Rani Therapeutics Holdings, Inc. (NASDAQ:RANI), it sends a favourable message to the company's shareholders.

Although we don't think shareholders should simply follow insider transactions, logic dictates you should pay some attention to whether insiders are buying or selling shares.

See our latest analysis for Rani Therapeutics Holdings

Rani Therapeutics Holdings Insider Transactions Over The Last Year

The Independent Director Jean-Luc Butel made the biggest insider purchase in the last 12 months. That single transaction was for US$102k worth of shares at a price of US$2.03 each. That implies that an insider found the current price of US$2.19 per share to be enticing. Of course they may have changed their mind. But this suggests they are optimistic. If someone buys shares at well below current prices, it's a good sign on balance, but keep in mind they may no longer see value. The good news for Rani Therapeutics Holdings share holders is that insiders were buying at near the current price.

While Rani Therapeutics Holdings insiders bought shares during the last year, they didn't sell. The chart below shows insider transactions (by companies and individuals) over the last year. If you want to know exactly who sold, for how much, and when, simply click on the graph below!

Rani Therapeutics Holdings is not the only stock insiders are buying. So take a peek at this free list of under-the-radar companies with insider buying.

Insider Ownership Of Rani Therapeutics Holdings

For a common shareholder, it is worth checking how many shares are held by company insiders. We usually like to see fairly high levels of insider ownership. Our data suggests Rani Therapeutics Holdings insiders own 2.7% of the company, worth about US$3.2m. We do note, however, it is possible insiders have an indirect interest through a private company or other corporate structure. We prefer to see high levels of insider ownership.

So What Does This Data Suggest About Rani Therapeutics Holdings Insiders?

There haven't been any insider transactions in the last three months -- that doesn't mean much. But insiders have shown more of an appetite for the stock, over the last year. While we have no worries about the insider transactions, we'd be more comfortable if they owned more Rani Therapeutics Holdings stock. While it's good to be aware of what's going on with the insider's ownership and transactions, we make sure to also consider what risks are facing a stock before making any investment decision. To help with this, we've discovered 4 warning signs (1 is a bit unpleasant!) that you ought to be aware of before buying any shares in Rani Therapeutics Holdings.